Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING - Significant expense categories (Details)

v3.25.2
SEGMENT REPORTING - Significant expense categories (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Loss from operations $ (10,184,661) $ (2,713,706) $ (17,644,757) $ (6,390,357)
Net Loss: $ 10,117,029 $ 2,623,657 $ 17,464,932 $ 6,258,745
Other segment items description Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense
Life science | Operating segment        
Operating expenses:        
PMN310 development program costs $ 8,050,610 $ 1,073,864 $ 12,776,951 $ 2,623,174
Other non-employee research and development costs 220,669 194,620 498,584 418,972
Employee costs 1,053,258 536,021 2,496,325 1,117,031
Other general and administrative costs 860,124 909,201 1,872,897 2,231,180
Loss from operations 10,184,661 2,713,706 17,644,757 6,390,357
Other segment items (67,632) (90,049) (179,825) (131,612)
Net Loss: $ 10,117,029 $ 2,623,657 $ 17,464,932 $ 6,258,745